Partnering with exceptional research teams worldwide

Cambrian is developing a wide array of new therapeutics targeting the drivers of biological aging. We work with top tier academic institutions to create Cambrian Pipeline Companies (PipeCos) across the US and Europe.

Developing therapeutics with the potential to both treat and prevent disease

Molecular alteration programs

Pre-Clinical Development

Clinical Trials

Discovery

Hit

Lead

Candidate

Phase I

Phase II

Phase III

SNS-301

Phase 2

Clinical Trial

-

Phase 2

SNS-401

Candidate

Clinical Trial

-

Candidate

SNS-VISTA

Lead

Clinical Trial

-

Lead

CAM-9782

Lead

Clinical Trial

-

Lead

Cellular dysfunction programs

Pre-Clinical Development

Clinical Trials

Discovery

Hit

Lead

Candidate

Phase I

Phase II

Phase III

CAM-7276

Lead

Clinical Trial

-

Lead

CAM-5746

Hit

Clinical Trial

-

Hit

CAM-5747

Hit

Clinical Trial

-

Hit

CAM-7967

Hit

Clinical Trial

-

Hit

CAM-2789

Discovery

Clinical Trial

-

Discovery

CAM-3594

Discovery

Clinical Trial

-

Discovery

Tissue degeneration programs

Pre-Clinical Development

Clinical Trials

Discovery

Hit

Lead

Candidate

Phase I

Phase II

Phase III

CAM-1108

Candidate

Clinical Trial

-

Candidate

CAM-1721

Candidate

Clinical Trial

-

Candidate

CAM-2634

Candidate

Clinical Trial

-

Candidate

CAM-4265

Lead

Clinical Trial

-

Lead

CAM-7520

Lead

Clinical Trial

-

Lead

CAM-4628

Hit

Clinical Trial

-

Hit